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Highlights 
 We present an innovative in vitro model to better reflect the in vivo environment. 
 Human 3D microtissues (co-culture of cardiomyocytes and fibroblasts) were used. 
 Cells were exposed to PBPK-based repetitive dosing profile for two weeks. 
 Our approach can retrieve mechanisms of DOX toxicity known to occur in vivo.  
 Using physiologically relevant doses during toxicological research is important. 
 
Abstract 
Doxorubicin (DOX) is a chemotherapeutic agent of which the medical use is limited due to cardiotoxicity. 
While acute cardiotoxicity is reversible, chronic cardiotoxicity is persistent or progressive, dose-
dependent and irreversible. While DOX mechanisms of action are not fully understood yet, 3 toxicity 
processes are known to occur in vivo: cardiomyocyte dysfunction, mitochondrial dysfunction and cell 
death. We present an in vitro experimental design aimed at detecting DOX-induced cardiotoxicity by 
obtaining a global view of the induced molecular mechanisms through RNA-sequencing. To better 
reflect the in vivo situation, human 3D cardiac microtissues were exposed to physiologically-based 
pharmacokinetic (PBPK) relevant doses of DOX for 2 weeks. We analysed a therapeutic and a toxic 
dosing profile. Transcriptomics analysis revealed significant gene expression changes in pathways 
related to “striated muscle contraction” and “respiratory electron transport”, thus suggesting 
mitochondrial dysfunction as an underlying mechanism for cardiotoxicity. Furthermore, expression 
changes in mitochondrial processes differed significantly between the doses. Therapeutic dose reflects 
processes resembling the phenotype of delayed chronic cardiotoxicity, while toxic doses resembled 
acute cardiotoxicity. Overall, these results demonstrate the capability of our innovative in vitro approach 
to detect the three known mechanisms of DOX leading to toxicity, thus suggesting its potential 
relevance for reflecting the patient situation. Our study also demonstrated the importance of applying 
physiologically relevant doses during toxicological research, since mechanisms of acute and chronic 
toxicity differ.  AC
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1. Introduction 
Doxorubicin (DOX, also known by the brand name Adriamycin) is a chemotherapeutic agent belonging to 
the class of anthracyclines, which are cytostatic antibiotics. DOX was isolated from Streptomyces 
peucetius var. caesius in 1967[1] and it is still one of the most frequently used anti-cancer agents for 
treating a variety of cancers (e.g. hematological cancers, soft-tissue tumors, and solid tumors), even 
though it causes severe side effects. Next to nausea, vomiting, alopecia, myelosuppression, stomatitis, 
and gastrointestinal disturbances, DOX is known to induce cardiotoxicity. Cardiotoxicity is classified as 
acute or chronic. Acute cardiotoxicity may already occur during treatment with a single high dose or 
within 2-3 days after multiple DOX treatments[2, 3]. Though its prevalence is higher than for chronic 
cardiotoxicity, these side effects are reversible and clinically manageable. A chronic cardiotoxic 
phenotype may emerge between one month and decades after DOX treatment. This persistent or 
progressive cardiotoxicity is dose-dependent and irreversible. In cases where congestive heart failure 
has developed, the prognosis for the patient is poor, with a mortality rate of 50% within one year[3-7]. 
Given this dose-dependency, a maximum cumulative dose of 450 – 600 mg/m2 is recommended for 
DOX[8, 9]. 
DOX mechanisms of action are not fully understood yet. Nevertheless, it is generally accepted that the 
main mode of action is related to killing dividing cells. These effects are more severe for tumor cells 
since these cells divide more rapidly than non-cancer cells. However, DOX is not tumor cell-specific and 
can accumulate in the nucleus and mitochondria of heart, liver and blood cells, thereby contributing to 
toxic side effects, in particular chronic cardiotoxicity, even at therapeutic doses[5]. DOX has been found 
to 1) intercalate into DNA, 2) target DNA topoisomerases, and 3) generate reactive oxygen species (ROS) 
[10-12]. The first two processes inhibit unwinding of DNA, DNA replication, RNA transcription and 
protein biosynthesis. As a result, proliferation of dividing cells is also inhibited [9, 13].  This is thought to 
be the efficacy of the anti-cancer effects of DOX, while ROS generation is mainly ascribed to toxic 
effects[14]. ROS can be generated as a result of mitochondrial dysfunction, but also by the oxidative 
semiquinone formed at complex I of the electron transport chain (ETC) during DOX metabolism. The 
induced oxidative stress may damage cells and cause cell death[8, 11]. Other detrimental actions of DOX 
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can be related to death of non-cancer cells or to decreased cardiomyocyte functioning, which may partly 
result from mitochondrial dysfunction causing an imbalance in cellular energetics. Therefore, any effect 
of DOX on mitochondria structure or function can cause cardiomyocyte dysfunction and thereby 
cardiotoxicity[15]. The detrimental actions of DOX, known to occur in vivo, can thus be summarized into 
3 toxicity processes: cardiomyocyte dysfunction, mitochondrial dysfunction and cell death. However, it 
should be noted that the split between efficacy and detrimental actions is not fully justified because of 
overlapping processes, such as oxidative stress and cell death.  
To predict molecular mechanisms underlying long term toxicity, toxicological risk assessment 
traditionally relies on animal models[16]. However, notably due to increasing ethical pressure, the field 
has to reduce the amount of animal experiments. In this article, we present an innovative in vitro 
experimental design aimed to detect cardiotoxicity by obtaining a complete view of the induced 
mechanisms of a compound. By better reflecting the human in vivo conditions, we aim to find an in vitro 
model capable of reliably replacing animal models used within the field of toxicology and drug safety 
testing. First, instead of the regularly used monolayer cell cultures, a Human 3D cardiac microtissue 
(InSphero, SWL) model was used, which better resembles the in vivo heart [17-19]. This in vitro spheroid 
cell model contained approximately 4000 iPSC-derived human cardiomyocytes and 1000 cardiac 
fibroblasts. Second, in contrast to using a relatively high dose to treat the cells, physiologically based 
pharmacokinetic (PBPK) modelling[20] was included within the study design to better reflect the in vivo 
exposure. PBPK simulates the absorption, distribution, metabolism and excretion of a specific dose of 
DOX within the human body, therefore enabling us to predict the concentration to which a specific 
organ is exposed over time. The PBPK model was used to design a two weeks repetitive dosing profile in 
which microtissues were exposed to a decreasing dose over each day by means of 3 medium changes. 
The microtissues were exposed to either a therapeutic or a toxic dose of DOX using this PBPK-based 
repetitive dosing profile, and functional parameters for mitochondrial function and programmed cell 
death were assessed. Finally, by applying next-generation total RNA-sequencing to ribo-depleted RNA 
samples, we were able to analyze global changes in gene expression. By using this innovative 
experimental in vitro experimental design, we were able to successfully detect biological changes in the 
three main identified toxicity processes of DOX (cardiomyocyte dysfunction, mitochondrial dysfunction 
and cell death).  
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2. Methods  
2.1 Samples 
The human 3D cardiac microtissue (InSphero, SWL) model was used, containing approximately 4000 
iPSC-derived human cardiomyocytes (female Caucasian donor) and 1000 cardiac fibroblasts (male 
Caucasian donor) per microtissue. The microtissues were cultured in 3D InsightTM Human Cardiac 
Microtissue Maintenance Medium (InSphero, Cat #CS-07-010-01).  
2.2 PBPK model establishment 
A PBPK model for DOX was established with the PBPK modelling software PK-Sim following a previously 
described workflow[21]. In particular, the model was used to quantify interstitial heart concentrations 
following administration of therapeutic and toxic drug doses. These concentration profiles were 
subsequently translated into discrete daily exposure profiles (Figure 1a, b). During model establishment, 
model predictions of blood plasma DOX concentrations were compared with literature data for 
parameter identification[22]. In a next  step, the model was validated  with further PK data4 (Figure 1c). 
Once daily therapeutic doses (0.415 mg*kg-1) were taken from literature while toxic doses (1.18 mg*kg-
1) were estimated based on in vitro dose-response experiments. The toxic dose was estimated, such 
that the in vitro drug exposure (AUC) after 7 days resulting in a 20 % loss of cell viability (IC20) was equal 
to the unbound drug exposure in the interstitial heart compartment of the PBPK model after a 7 day 
once daily drug administration regimen (Figure 1a).  
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Figure 1: Doxorubicin PBPK 
model simulations. a) 
Simulations of DOX interstitial 
heart concentration profiles 
following a therapeutic (green) 
and toxic (red) once daily 
dosing regimen with 
experimental sampling points 
(black circles). b) Exemplary 
translation of PBPK simulations 
into discrete in vitro assay 
concentration with equal 
exposure, applied to cardiac 
microtissues for the first three 
days. c) Validation of PBPK 
model predicted DOX blood 
plasma concentrations with 
literature data[23].   
 
2.3 Exposure 
To accomplish the PBPK-based repetitive dosing profile described above, the medium of the 
microtissues was changed three times daily on working days with the PBPK-determined DOX 
concentrations (Sigma D1515, Cat #25316-40-9). These were administered using stock solutions of the 
compound dissolved in DMSO. As control, microtissues exposed to similar end concentrations of DMSO 
were used. 7 time points (2, 8, 24, 72, 168, 240 and 336 hours) were sampled in triplicate during the 2 
weeks treatment period. For each sample, 36 microtissues were incubated separately, and subsequently 
pooled before RNA extraction in order to generate sufficient input material for NGS analysis. 
2.4 RNA sequencing & Data processing 
From the exposed microtissues, total RNA was isolated using Qiagen AllPrep DNA/RNA/miRNA Universal 
Kit (Cat #80224). The sample was depleted of ribosomal RNA using the Illumina RiboZero Gold kit (Cat 
#MRZG12324) and prepared for sequencing using Lexogen SENSE total RNA library preparation kit (Cat 
#009.96). After library preparation, the samples were sequenced on the HiSeq2500 (100bp paired-end). 
A pool of all DOX samples was sequenced on all 8 lanes of a flow cell. The same was done for the control 
samples. Control samples were sequenced with an average of 51.2 million raw reads, therapeutic DOX 
with 20.3 million reads and toxic DOX with 18.7 million. Because the sequencing reads still contained 
Lexogen adapter sequences, the first 12 bases of the 5’end of all reads were removed using 
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Trimmomatic version 0.32 [24]. The quality of the sequencing data was checked using FastQC version 
0.11.3 [25] before and after trimming.  
2.5 Gene expression analysis 
For each sample, sequencing reads were mapped to the GENCODE version 26 (GRCh38) - Ensembl 88 
(Comprehensive gene annotation) using the Genedata ProfilerTM version 10.1, which incorporates the 
splice junction mapper STAR version 2.5.2b and Cufflinks based algorithms for transcript abundance 
estimation.  
The quality of the samples was assessed according to the amount of (mapped) reads, Cook’s distance, 
hierarchical clustering, principal component analysis, and sample dispersion. 1 replicate of DOX toxic 
240h was excluded because of low read count. 
Differentially expressed genes (DEGs) were determined using DESeq2 version 1.14.1 [26]. For each 
specific time point, 2 comparisons were performed: 1) therapeutic dose vs DMSO control; 2) toxic dose 
vs DMSO control. Samples of all time points for both doses were normalized together and the contrast 
function was used to extract differentially expressed genes for each time point, ensuring comparability 
between time points. Genes were being considered as differentially expressed when q<0.05. 
2.6 Biological interpretation 
For each dose and time point, lists of DEGs (depleted of ribosomal genes) were used as input for 
pathway over-representation analysis (ORA) using CPDB release 32 [27]. The Reactome database version 
61 was selected because it is curated, focuses on molecular mechanisms and includes pathway 
hierarchy[28]. Results from this analysis was visualized using Omix visualization version 1.9.20 [29]. 
2.7 Functional assessments: ATP measurement, Caspase3/7 assay and Oxygen consumption 
For measurement of ATP, Promega's CellTiter Glo 3D (Cat #G9683) was used according to 
manufacturer’s protocol. In short, the microtissues were incubated for 30min with luciferase reagent 
and the luminescence was measured. 
Apoptosis induction was measured using Promega's caspase-Glo® 3/7 assay (Cat #G8092) according to 
manufacturer’s protocol. Briefly, the Z-DEVD-aminoluciferin substrate is cleaved by caspase 3/7, 
releasing a substrate for luciferase (aminoluciferin), resulting in measurable luminescence.  
Mitochondrial function after 2 hours and 7 days of DOX treatment was assessed by measurement of 
extracellular oxygen consumption using Luxcel’s MitoXpress® Xtra Oxygen Consumption Assay (Cat #MX-
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200) according to manufacturer’s protocol. In short, oxygen quenches the MitoXpress® Xtra probe, 
making the measured fluorescent signal, inversely proportional to the oxygen concentration.  
2.8 Mitochondrial model 
The computational mitochondrial model[30] for proteomics analysis was extended to evaluate the 
expression changes of genes functioning in mitochondria. The original model contained reactions of 
metabolites and involved protein complexes. For each protein complex represented in the model, the 
corresponding genes coding for each individual protein subunit were added.  
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3. Results 
In order to investigate mechanisms of DOX-induced toxicity, human 3D cardiac microtissues were 
exposed to DOX for two weeks with either a therapeutic dose (DTHE) or a toxic dose (DTOX) using a PBPK 
based dosing profile. To this end, the medium of the microtissues was changed three times per workday 
with a decreasing dose. Samples were generated after 2, 8, 72, 168, 240 and 336 hours of DOX exposure 
for both doses (Figure 2A).  
Molecular effects of DOX on the cardiac cell were investigated using RNA-sequencing. The amount of 
differentially expressed genes (DEGs) increased over time (Figure 2B), except for a temporary decrease 
in DEGs at 240 hours of DTHE. Consistently across all time points, more DEGs were detected during 
exposure with DTOX than with DTHE. Of these DEGs, 80% were protein-coding genes.  
 
Figure 2: DOX exposure over time. A) PBPK-based dosing profile of cardiac microtissues, with DTHE in green and DTOX in red. 
Times at which samples are obtained for analysis are depicted with blue triangles. B) Amount of DEGs detected at each time 
point, with DTHE in green, DTOX in red and protein-coding DEGs in dark and non-coding DEGs in light.   
3.1 Identifying known DOX pathways in vitro 
An overview of the effects of DOX on the whole cardiac cell was investigated to identify processes linked 
to DOX toxicity. This was done through pathway overrepresentation analysis (ORA). Overrepresented 
pathways were visualized in supplementary figure 1. More significantly overrepresented pathways were 
identified for DTHE compared to DTOX. This in combination with the higher amount of DEGs detected for 
DTOX compared to DTHE indicates less specific cellular reactions for DTOX. While therapeutic DOX exposure 
affects many cellular processes, the most significantly affected pathways throughout DOX treatment are 
“TCA cycle & respiratory electron transport” (qmedian 2.92∙10-6) and “Striated muscle contraction” (qmedian 
9.3∙10-6). These pathways can be related back to detrimental actions of DOX. Therefore, toxicity 
processes (cardiomyocyte dysfunction, mitochondrial dysfunction and cell death) were investigated in 
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more detail (Figure 3), to determine whether our in vitro model expressed similar toxicity pathways as 
reported in literature for DOX.  
 
Figure 3: Specific toxicity 
processes affected by 
DOX. Visualization of 
overrepresented 
pathways, with DTHE on 
the left and DTOX on the 
right. Black elipses 
identify clusters based 
on biological processes. 
Pathways (rectangles) 
were included when 
significantly 
overrepresented after 
DOX exposure minimally 
at 1 time point and at 1 
dose, or in case the 
pathway was crucial for 
maintaining hierarchical 
links between the 
pathways. Coloured 
pathway names indicate 
pathways that were 
significantly 
overrepresented at the 
majority of time points 
(median of q-values 
<0.05). Bars on top of 
the pathway names 
depict up- and 
downregulation (blue 
and red resp.) per time 
point. The fill level 
corresponds to the 
percentage of DEGs 
detected (either up or 
down) in the pathway. 
The bars also depict if 
gene expression changes 
were significant at 
individual time points, 
with bright red and blue 
representing significant 
overrepresentation of 
the pathway at the 
specific time point, while 
faded colours are not 
significantly 
overrepresented at the 
given time. 
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Both DOX doses clearly induced “striated muscle contraction”, the main pathway related to 
cardiomyocyte dysfunction. Both doses displayed also a decreasing amount of upregulated genes over 
time combined with an increase of downregulated genes. For DTOX, the amount of downregulated genes 
was always higher than of upregulated genes, while DTHE displayed more upregulated genes until 240 
hour of treatment. In “cellular senescence”, more DEGs were observed for DTOX compared to DTHE, while 
the pathway was found significantly overrepresented for DTHE at more time points than for DTOX. This 
phenomenon is common in ORA and caused by the higher amount of DEGs and less specific cellular 
reactions of DTOX. More striking were the differences between doses with respect to metabolic processes 
within the mitochondria. While DTHE induced upregulations over time, DTOX induced downregulations at 
the end of the DOX treatment period(168h – 336h). Because mitochondria are involved in cell death and 
ATP generation necessary for cardiac contractile function, this dose-dependent difference in DOX-
induced expressions of genes involved in mitochondrial processes may represent the underlying cause 
for differences in phenotypes for chronic or acute cardiotoxicity. Therefore, it is of interest to analyze 
mitochondrial dysfunction in more detail. 
3.2 Functional assessment of microtissue viability  
With respect to the ATP content of DOX-treated cells, the two analyzed doses (Figure 4A) were 
significantly different (p-value 0.027) from each other. For DTOX, ATP content decreases slightly until 72h, 
followed by a steep decrease in which ATP content is lower than the control. For DTHE, a stable ATP 
content of approximately 20 pmol/microtissue is measured, except for a temporary drop at 240 hours of 
exposure. Between 24h and 168h, ATP content is increased compared to the DMSO controls. Relating 
these results to the gene expression changes observed in the pathway “Formation of ATP by 
chemiosmotic coupling”, indicates that increased gene expression is necessary for maintaining stable 
ATP content, while ATP content drops when no changes in gene expression are taking place. This 
suggests a decreased functionality and/or viability of the cardiac microtissues. Though cell death was 
not obviously detected on the gene level, this decreased viability was reflected from the caspase 3/7 
assay results performed at 2 and 168 hours of DOX exposure (Figure 4b). Here, caspase activity was 
more than twice as high compared to UNTR (p2h= 0.001; p168h=0.022) ando DTHE (p2h= 0.030; p168h=0.039. 
This difference in cell viability was also indirectly confirmed by the size of the microtissues, which 
visually decreased over time for DTOX but not for DTHE.  
After 2 hours of DOX exposure, oxygen consumption was decreased by approximately 11% at both doses 
(pTHE= 0.061; pTOX=0.048). After 168 hours of exposure, a difference oxygen consumption induced by the 
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two doses was visible, with a decrease of 15% (p=0.369) for DTHE and 33% for DTOX (p=0.064). While the 
decrease for DTOX can be partially caused by a lower amount of viable cells per microtissue, the decrease 
in oxygen consumption for DTHE suggests decreased mitochondrial function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Functional assessment of microtissue viability.  
A) Changes in ATP content of DOX exposed cardiac 
microtissues compared to DMSO control samples, with 
DTHE in green, DTOX in red and DMSO control in black. B) 
Caspase activity measurements at 2 & 168 hours of 
exposure compared to untreated microtissues. C) Example 
of a cardiac microtissue at each sampling time point to 
indicate microtissue size. D) Oxygen consumption 
measurements at 2 & 168 hours of exposure compared to 
untreated microtissues. * significantly different from 
control; ** significantly different from control and DTHE 
 
 
3.3 Mitochondrial effects of DOX exposure 
To elucidate the effects of DOX on genes functioning in mitochondria, DEGs were mapped onto the 
computational mitochondrial model [30] adapted for transcriptomics data (Figure 5). As expected, the 
mitochondrial model showed major differences between the two doses. DTHE displayed a majority of 
upregulated genes, while DTOX displayed more downregulations, especially at later time points.  
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Figure 5: Transcriptomics mitochondria model showing effects of DOX on the mitochondria over time.  
Upper panel display the therapeutic dose, lower panel correspond to the toxic dose. Purple ovals depict protein complexes and 
the genes encoding for subunits are displayed next to this in rectangles. On top of each gene, the boxes display the expression 
change over time, where each box corresponds to a specific time point (blue= upregulation, red= downregulation, grey= not 
significantly changed). 
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3.3.1 Detoxification of ROS 
Detoxification of ROS (bottom left of Figure 5) was activated to the same extent for both doses, though 
there are slight differences in the final step of ROS detoxification, in which H2O2 is converted to water. 
While for DTHE this reaction was mainly catalyzed by peroxiredoxin (PRX), for DTOX this reaction was 
carried out by both peroxiredoxin (PRX) and glutathione peroxidase (GPx). Overall, the upregulations 
found in these ROS detoxification genes indirectly indicated an increase in ROS formation in response to 
DOX.  
3.3.2 Electron transport chain and formation of ATP 
Table 1: DOX effect on ETC complexes, overview of affected genes at minimally one time point 
Complex Genes in 
complex 
Affected genes 
(number / % of 
complex) 
Genes upregulated 
(number / % of 
complex) 
Genes 
downregulated 
(number / % of 
complex) 
Genes significant >4 time points 
(number / % of complex) 
  DTHE DTOX DTHE DTHE DTOX DTOX DTHE DTOX 
I 53 21 / 39.6 25 / 47.2 19 / 35.8 2 / 3.8 12 / 22.6 12 / 22.6 NDUFA12, NDUFB9, 
NDUFC1, NDUFAF3 
MT-ND6, NDUFB9, 
NDUFC1 
II 8 2 / 25.0 3 / 37.5 1 / 12.5 1 / 12.5 1 / 12.5 1 / 12.5 SDHA - 
III 12 7 / 58.3 5 / 41.7 7 / 58.3 0  2 / 16.7 3 / 25.0 UQCR10, UQCRH, 
UQCRQ, UQCC2 
UQCRQ 
IV 29 13 / 44.8 13 / 44.8 10 / 34.5 3 / 10.3 7 / 24.1 6 / 20.7 COX6B1, COX6C, 
COX7C, COX8A, 
COX14 
COX6A2, COX7A1, 
COX8A 
V 21 11 / 52.4 12 / 57.1 10 / 47.6 1 / 4.8 8 / 38.1 4 / 19.0 ATP5E, ATPG3, 
ATP5L 
ATP5S 
Dose-dependent differences were most noticeable in the complexes of the ETC (top left of Figure 5). The 
overall amount of genes affected (minimally at 1 time point) was similar between the doses, with 
complex I expressing the most DEGs. Because of the difference in amount of genes per complex, 
comparison in percentage of complex gave a better overview of the DOX effect (Table 1). Complex III 
was mostly affected for DTHE, while complex V (also known as ATP synthase) was highly affected by both 
doses. Complex II was the least affected by DOX exposure. Dose-dependent differences were mostly 
observed through the direction of expression changes. Affected genes for DTHE were mostly upregulated, 
while DTOX displayed an increase in downregulated genes, especially in later time points. Names of genes 
that were most highly affected by DOX exposure (significantly affected minimally at 4 time points) were 
also included in Table 1. Figure 6 depicts the log2 fold changes of these genes. Only gene expression 
changes of highly affected complex V genes were highly correlated to the changes observed in ATP 
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content (Figure 4A), suggesting that the ATP level modification induced by DOX are directly monitored 
by the expression level of the genes involved in complex V.   
Overall, DOX-induced gene expression changes in the ETC were observed at both doses, though these 
changes indicate different underlying processes between the doses, discriminating between the 
phenotype of delayed chronic cardiac toxicity and acute cardiotoxicity. 
 
Figure 6: Log2 fold changes of highly affected ETC genes. Genes with significant expression changes minimally at 4 time points 
were depicted for each ETC complex, with DTHE in green and DTOX in red. Significant log2 fold changes are indicated with a 
marker, while non-significant changes are depicted with only a line.  
4. Discussion 
The main objective of this study was to validate our novel in vitro experimental design for its use in 
predictive toxicological research. For this purpose, we analyzed cardiotoxic effects of doxorubicin (DOX). 
Our in vitro approach was designed to improve the resemblance to in vivo situations. This was achieved 
by using novel human 3D cardiac microtissues. This spheroid cell model contains a co-culture of iPSC-
derived human cardiomyocytes and cardiac fibroblasts, better resembling the in vivo heart than mono-
culture monolayers. Furthermore, while standard toxicological research is being done with short time 
series and exposures at one specific dose, we applied a 2 week PBPK-based repetitive dosing profile that 
resembles in vivo drug concentrations in patients with one drug administration per day. The dose of 
DOX to which a patient’s heart is exposed was calculated based on pharmacokinetic simulations of the 
absorption, distribution, metabolism and excretion of DOX. In vitro, the medium of the cardiac 
microtissues was changed three times daily with calculated DOX doses, resulting in the highest dose in 
the morning and the lowest dose in the evening of each working day during the 2 week exposure. The 
experimental design also included the exposure of two different dosing profiles, one based on 
therapeutic doses, as administered to a patient, and one based on a toxic dose. From these samples, 
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RNA was extracted and sequenced to determine if this novel in vitro approach is able to retrieve the in 
vivo toxicity mechanisms known for DOX. 
We used three detrimental actions of DOX which are known to occur in vivo (cardiomyocyte dysfunction, 
mitochondrial dysfunction and cell death) to determine that the in vitro approach was able to retrieve 
the in vivo toxicity pathways known for DOX [8, 11, 14, 15]. Results from ORA indicated less specific 
cellular reactions for DTOX, observed by the combination of more DEGs and less overrepresented 
pathways compared to DTHE. Furthermore, ORA identified toxicity of DOX by gene expression changes in 
the pathways of “striated muscle contraction”, “TCA cycle & respiratory electron transport” and “cellular 
senescence”. Gene expression changes in “striated muscle contraction” (cardiac function) and “cellular 
senescence” (cell death) displayed similar patterns, while mitochondrial processes (“TCA cycle & 
respiratory electron transport”) displayed significantly upregulated processes for DTHE and non-
significantly downregulated processes for DTOX. A central link between the toxicity pathways is the 
“formation of ATP by chemiosmotic coupling”. Mitochondrial gene expression changes correlated with 
ATP measurements, in which DTHE displays a relatively stable ATP content, while ATP content for DTOX 
decreased drastically over time. From this, we hypothesize that both doses induce toxicity, but the 
underlying processes between the doses are different, with its origin resulting from differences in 
mitochondrial functioning. Therapeutic doses reflect processes underlying the phenotype of delayed 
chronic cardiac toxicity, while toxic doses reflect processes of acute cardiotoxicity.  
A more detailed analysis of mitochondrial dysfunction was done by investigating the 5 complexes of the 
ETC and activation of ROS detoxification processes. Mainly complex I, but also complex III, represent the 
sites of premature electron leakage to oxygen, resulting in the generation of ROS. Inefficiency of 
complex I can therefore result in increased ROS generation and oxidative stress. Furthermore, complex I 
is also a known interaction site for DOX, where it is reduced to form the oxidative semiquinone, which in 
turn, reduces oxygen to the highly reactive superoxide, returning DOX to its original state. Besides 
functioning as signaling molecules, ROS can damage proteins, nucleic acids and lipids in the cell. In order 
to prevent this, the cell is equipped with mechanisms to detoxify ROS. Gene expression changes 
indicated a similar increase in ROS detoxification between the doses. This confirms that ROS generation 
induced by DOX is indeed taking place in the in vitro model. Generated ROS is part of a positive feedback 
loop, in which more ROS results in more mitochondrial DNA (mtDNA) damage, leading to defects in the 
ETC complex, which results in increased ROS formation. Though uncertain whether this loop is initiated 
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by generated ROS or if mtDNA damage is induced by DOX directly, this could explain the persistent and 
cumulative nature of DOX cardiotoxicity, even in the absence of the drug itself [5]. 
The detailed mitochondrial model also revealed major effects of DOX on the ETC and ATP production. 
Changes in this process differed significantly between the doses, with upregulations across time for DTHE 
and a majority of downregulations in later times for DTOX. Most DEGs were detected in Complex I for 
both doses. Complex I is the starting point for transferring electrons form NADH through the ETC in 
order to generate ATP [31, 32]. Also highly affected was Complex V (ATP synthase), which acts as a 
membrane channel for protons to be returned to the matrix. The flow back of protons gains the energy 
needed to convert ADP to ATP. The intermediate complexes of the ETC were also affected, though 
complex II only slightly. Because complex II  is the only ETC complex that is completely encoded by the 
nucleus, and therefore less susceptible to mitochondrial ROS[14], this strengthens the involvement of 
the previously noted positive feedback loop between ROS, mtDNA damage and defects in ETC 
complexes. This process is also supported by the expression profile in mitochondrial encoded genes for 
subunits of complex I (MT-ND genes), which displayed changes in toxic dose, but not in therapeutic dose. 
The downregulations in gene expression at the later time points of toxic DOX exposure indicates the 
failure of ATP production through ETC. The decrease in ATP content of the microtissues was a 
continuous process throughout the exposure, a pattern that was also observed for ATP5S, the most 
affected gene in complex V. This gene, also known as factor B, is responsible for the energy transduction 
activity of the ATP synthase complex[33]. Though, it is unlikely that a defect of this one gene was solely 
responsible for the ATP decrease. Decreased effectiveness of the ETC may also be due to decreased 
oxygen availability, oxygen being consumed by DOX during ROS generation. Therefore, the ETC has less 
protons available to establish the proton gradient necessary for ATP production [14]. However, it seems 
more likely that the heterogeneity of DOX exposure causes malfunctioning cells in the outer layers of 
the microtissue to die, leaving a decreased amount of viable cells at the core to produce ATP. Because 
RNA-sequencing detects the mean gene expression of all living cells in the sample, this effect might not 
be significantly present to be detected in our data analysis. The detected decrease in gene expression at 
later time points therefore indicates adversity of the microtissue.  This adversity was also observed in 
pathway analysis, where cellular processes are affected in less specific ways, indicating deregulation of 
the cell which may result in cell death. Though not observed by gene expression changes, cell death is 
observed in the cardiac microtissues at toxic doses of DOX through a decrease in microtissue size and 
increase of caspase 3/7 activity. 
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In microtissues exposed to therapeutic doses, the DOX effect was also not equally distributed over the 
mitochondria present in the cells of the cardiac microtissue. Only a small amount of cells in the outer 
layer of the microtissue died, as could be seen from the small increase in caspase activity and a decrease 
in microtissue size that is hardly visible. However, an increase in gene expression of mitochondrial and 
ETC genes was necessary in order to maintain cellular ATP content, indicating a possible adaptation 
response in which less affected mitochondria compensate for highly affected mitochondria. However, 
this adaptation response may not be sufficient for maintaining cardiac function, because genes involved 
in striated muscle contraction were already showing decreasing expression level. Since the regenerative 
capacity of the heart is limited to ventricular remodelling, cumulative toxicity surpasses the point to 
which the organ can adapt, thereafter resulting in a delayed phenotype of heart failure, as is observed in 
patients with chronic cardiotoxicity after DOX treatment [4, 15]. 
5. Conclusion 
Overall, these results confirm that our in vitro approach, based on 3D human microtissues exposed to an 
innovative 2 weeks PBPK dosing profile of DOX, is able to retrieve the known mechanisms of DOX 
toxicity. This new in vitro toxicity model can be extended to other 3D human microtissues, such as the 
already available liver model from primary hepatocytes. 
The insights from the current study demonstrate the importance of applying physiologically relevant 
dosing profiles during toxicological research. Many studies on DOX effects have been performed with 
single and/or extremely high doses that do not reflect - and may even obscure - the true mechanisms of 
toxicity. Therefore, controversy in published results must be treated cautiously because of the risk of 
oversimplification and mixture of the different mechanisms of acute and chronic effects [14, 34].  
Ultimately, we believe that this novel approach, better mimicking the human in vivo condition, could 
replace animal models within the field of toxicology and drug safety testing.  
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